Ineffective Esophageal Motility Treatment Market to Reach US$ 6.4 Bn by 2030; Prioritization of COVID-19 Treatment to Hurt Near-term Growth


  • Published On : Jun 24, 2020

Ineffective esophageal motility treatment leads to a reduction in muscle damage and improved outcomes, improving quality of life and resulting in long-term benefits. Device-based treatment and IEMT drugs have already had a substantial impact on how symptoms of GERD and achalasia are treated. The first and the most important factor driving the growth of the ineffective esophageal motility treatment market is the increasing prevalence of gastroesophageal reflux disease. Other factors, such as intake of asthma medications and increasing geriatric population, are also responsible for driving the ineffective esophageal motility treatment market.

According to the latest report published by PMR, the global ineffective esophageal motility treatment market is projected to expand at a decent CAGR of around 6% during the forecast period (20202030).

Key Takeaways from Ineffective Esophageal Motility Treatment Market Study

  • Significant advantages of ineffective esophageal motility treatment; improving reimbursement scenario for surgical treatment devices; increasing awareness regarding gastric reflux disease; and large patient pool for GERD, dysphagia, achalasia, and burning chest pain are key factors propelling the growth of ineffective esophageal motility treatment market in developing regions.
  • North America is a prominent region the global ineffective esophageal motility treatment market, while East Asia is expected to offer lucrative growth opportunities, owing to the large population base and higher incidence of GERD and dysphagia.
  • Higher OTC antacid consumption is poised to drive the growth of the market.
  • Radiofrequency ablation systems with high level precision and procedural advantages over myotomy are expected to generate significant revenue in the long term.
  • Increasing adoption of ineffective esophageal motility treatment drugs for quick recovery as compared to device-based treatment marks higher revenue potential.
  • Raw material procurement issues, drug shortages, and reduced patient visits amidst the COVID-19 pandemic will adversely affect the growth of the ineffective esophageal motility treatment market in the near term.

“Procedural accuracy achieved by treatment devices and affordability of drug-based treatment are anticipated to drive the ineffective esophageal motility treatment market. Additionally, the large patient pool will bring in steady revenue opportunities," says a PMR analyst.

View Report Table of Contents, Figures, and Tables

New Product Launches by Key Players to Strengthen Market Presence

Key manufacturers in the ineffective esophageal motility treatment market are mainly focusing on research & development and introduction new & advanced treatment products. For example, LINX is the new and advanced version of the LINX reflux management device that is used for the transoral incision-less fundoplication process, which is one of the important procedures for the treatment of gastroesophageal reflux disease. The innovation of new & advanced products is a factor boosting the ineffective esophageal motility treatment market. In addition, Olympus Corporation has launched advanced versions of esophagoscopes, which have improved the treatment curve of gastroesophageal reflux disease. Manufacturers are focusing on extended indication list and higher reimbursement to draw demand and increase profitability. Alternatively, a key factor affecting the ineffective esophageal motility treatment market is the entry of generic drug manufacturers. Market leaders are constantly working on strengthening their strategies to gain market share.

What else is in the report?

Persistence Market Research offers a unique perspective and actionable insights on the ineffective esophageal motility treatment market in its latest study, presenting historical demand assessment of 20152019 and projections for 20202030, on the basis of product (drugs and devices), indication (GERD, dysphagia, achalasia, and burning chest pain), and end user (institutional sales and retail sales), across seven key regions.

For additional insights on how the growth of the ineffective esophageal motility treatment market will unfold over the next decade (2020 to 2030), write to the analyst at media@persistencemarketresearch.com

PMR’s Expertise in Life Sciences and Transformational Health

Our expert team of industry analysts comprising management graduates, medical professionals, engineers, and project managers provides insights on emerging therapy areas, diagnostic tools, medical devices and components, reimbursement and market access, biotechnology, and life science research products and services to equip decision makers with sound inputs and strategic recommendations. Click here to learn more about how we zero in on the critical aspects of this industry.

Back To Top